MX2021010556A - Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente. - Google Patents

Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.

Info

Publication number
MX2021010556A
MX2021010556A MX2021010556A MX2021010556A MX2021010556A MX 2021010556 A MX2021010556 A MX 2021010556A MX 2021010556 A MX2021010556 A MX 2021010556A MX 2021010556 A MX2021010556 A MX 2021010556A MX 2021010556 A MX2021010556 A MX 2021010556A
Authority
MX
Mexico
Prior art keywords
human
human animals
light chain
chain locus
igî
Prior art date
Application number
MX2021010556A
Other languages
English (en)
Inventor
John Mcwhirter
Faith Harris
Naxin Tu
Andrew J Murphy
Vera Voronina
Chunguang Guo
Natasha Levenkova
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021010556A publication Critical patent/MX2021010556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan animales no humanos (y/o células no humanas) y métodos para usar y producir los mismos, cuyos animales no humanos (y/o células no humanas) tienen un genoma que comprende secuencias que codifican anticuerpos humanos (es decir, genes de inmunoglobulinas). Los animales no humanos descritos en la presente descripción expresan anticuerpos que contienen cadenas ligeras Ig? humanas, en su totalidad o en parte. En particular, los animales no humanos proporcionados en la presente descripción se caracterizan, en algunas modalidades, por la expresión de anticuerpos que contienen cadenas ligeras Ig? humanas, en su totalidad o en parte, que están codificadas por secuencias que codifican cadenas ligeras Ig? humanas insertadas en un locus endógeno de cadena ligera Ig? de dichos animales no humanos. Se proporcionan, además, métodos para producir anticuerpos a partir de animales no humanos.
MX2021010556A 2016-11-04 2019-05-03 Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente. MX2021010556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
MX2021010556A true MX2021010556A (es) 2021-10-01

Family

ID=62025924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005256A MX2019005256A (es) 2016-11-04 2017-11-03 Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
MX2021010556A MX2021010556A (es) 2016-11-04 2019-05-03 Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019005256A MX2019005256A (es) 2016-11-04 2017-11-03 Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.

Country Status (24)

Country Link
US (2) US10820582B2 (es)
EP (3) EP3407709B9 (es)
JP (4) JP6884860B2 (es)
KR (4) KR20240055863A (es)
CN (2) CN109996441B (es)
AU (2) AU2017391167B2 (es)
BR (1) BR112019008675A2 (es)
CA (1) CA3038720A1 (es)
CY (1) CY1123491T1 (es)
DK (2) DK3407709T3 (es)
ES (2) ES2915609T3 (es)
HR (2) HRP20220888T1 (es)
HU (2) HUE052087T2 (es)
IL (2) IL308197A (es)
LT (2) LT3407709T (es)
MA (2) MA44091A (es)
MX (2) MX2019005256A (es)
PL (2) PL3407709T3 (es)
PT (2) PT3766343T (es)
RS (2) RS60886B1 (es)
RU (2) RU2021129958A (es)
SG (2) SG10201913483XA (es)
SI (2) SI3407709T1 (es)
WO (1) WO2018128691A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046744T2 (hu) * 2012-02-01 2020-03-30 Regeneron Pharma VL doméneket tartalmazó nehézláncokat expresszáló humanizált egér
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
CN109996441B (zh) 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
CN116874591A (zh) 2018-03-24 2023-10-13 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US20190380316A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
JP2022538885A (ja) * 2019-07-01 2022-09-06 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用法
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
CN116635413A (zh) 2020-12-23 2023-08-22 再生元制药公司 用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
EP4051700A1 (en) 2020-12-23 2022-09-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2003047336A2 (en) 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
WO2005007696A2 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
CN112715482B (zh) * 2008-12-18 2022-11-11 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
PL2564695T3 (pl) * 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
RS59413B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
DK2627773T3 (en) 2011-10-17 2017-10-02 Regeneron Pharma MOUSE WITH LIMITED IMMUNOGLOBULIN HEAVY CHAIN
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102038974B1 (ko) * 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
SI2840892T1 (en) * 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
CA2925723A1 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
KR102374379B1 (ko) 2014-06-06 2022-03-17 리제너론 파마슈티칼스 인코포레이티드 표적화된 좌를 변형시키는 방법 및 조성물
EP3155099B1 (en) 2014-06-23 2018-03-21 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
NZ731962A (en) 2014-11-21 2022-07-01 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
MX2017008190A (es) 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
CN109996441B (zh) 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物

Also Published As

Publication number Publication date
SG11201903344XA (en) 2019-05-30
PT3766343T (pt) 2022-05-30
HRP20220888T1 (hr) 2022-10-28
IL266282B2 (en) 2024-04-01
DK3766343T3 (da) 2022-06-20
EP3407709B1 (en) 2020-07-29
EP3766343A1 (en) 2021-01-20
JP2021090455A (ja) 2021-06-17
KR102658529B1 (ko) 2024-04-19
US20210029978A1 (en) 2021-02-04
RS60886B1 (sr) 2020-11-30
HUE052087T2 (hu) 2021-04-28
NZ753456A (en) 2021-08-27
CN109996441B (zh) 2022-02-08
EP3407709A1 (en) 2018-12-05
PT3407709T (pt) 2020-08-20
DK3407709T3 (da) 2020-08-31
RU2757665C2 (ru) 2021-10-20
LT3407709T (lt) 2020-10-12
IL266282A (en) 2019-06-30
EP3766343B1 (en) 2022-05-11
RU2021129958A (ru) 2021-11-02
AU2017391167B2 (en) 2024-02-15
KR20240055863A (ko) 2024-04-29
HRP20201403T1 (hr) 2020-11-27
PL3766343T3 (pl) 2022-09-26
ES2915609T3 (es) 2022-06-23
AU2017391167A1 (en) 2019-05-30
LT3766343T (lt) 2022-06-10
CN109996441A (zh) 2019-07-09
AU2024200582A1 (en) 2024-03-28
KR20230020550A (ko) 2023-02-10
MX2019005256A (es) 2019-08-05
PL3407709T3 (pl) 2021-01-11
RS63390B1 (sr) 2022-08-31
EP3407709B9 (en) 2021-10-06
KR102319069B1 (ko) 2021-11-01
JP2023053400A (ja) 2023-04-12
SI3407709T1 (sl) 2020-10-30
KR20210134059A (ko) 2021-11-08
SI3766343T1 (sl) 2022-06-30
HUE061980T2 (hu) 2023-09-28
IL308197A (en) 2024-01-01
JP2020501516A (ja) 2020-01-23
RU2019112589A3 (es) 2021-03-30
CA3038720A1 (en) 2018-07-12
CN114369157A (zh) 2022-04-19
CY1123491T1 (el) 2022-03-24
JP7386292B2 (ja) 2023-11-24
IL266282B1 (en) 2023-12-01
WO2018128691A8 (en) 2019-02-28
MA53935A (fr) 2021-12-22
KR20190076024A (ko) 2019-07-01
ES2823305T3 (es) 2021-05-06
US10820582B2 (en) 2020-11-03
EP4082334A1 (en) 2022-11-02
RU2019112589A (ru) 2020-12-04
KR102492433B1 (ko) 2023-01-30
US20180125043A1 (en) 2018-05-10
JP6884860B2 (ja) 2021-06-09
BR112019008675A2 (pt) 2019-07-09
SG10201913483XA (en) 2020-03-30
MA44091A (fr) 2018-10-24
JP2022130725A (ja) 2022-09-06
WO2018128691A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
MX2020005830A (es) Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
AR102888A1 (es) Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47
MY172718A (en) Humanized universal light chain mice
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
CY1121798T1 (el) Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα ζωα πλην του ανθρωπου για τη δημιουργια αυτων
SG10201902547SA (en) Non-human animals having a humanized signal-regulatory protein gene
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
NZ734504A (en) Humanized rodents that express heavy chains containing vl domains
MX358206B (es) Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
MY183188A (en) Non-human animals having a humanized b-cell activating factor gene
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
MX2018008701A (es) Roedores que tienen una region de diversidad de cadena pesada modificada geneticamente.
ZA202001389B (en) Non-human animals expressing humanized c1q complex